Roger Song
Stock Analyst at Jefferies
(3.93)
# 499
Out of 5,090 analysts
50
Total ratings
42.86%
Success rate
16.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $56.90 | +112.65% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $30.84 | +45.91% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.98 | +100.50% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $489.31 | +15.26% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.22 | +309.84% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.82 | +1,963.36% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $31.97 | +12.61% | 1 | Aug 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $41.67 | +29.59% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $10.61 | -43.45% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.12 | -2.34% | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.54 | +289.61% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $5.13 | +36.45% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $234.13 | +4.64% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.49 | +247.13% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $11.61 | -39.71% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $11.95 | +134.31% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $2.92 | +139.73% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $93.29 | -4.60% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $6.91 | +261.79% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $18.09 | +126.64% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $39.38 | -11.12% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $46.48 | +177.54% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $3.95 | +102.53% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $109.60 | -11.50% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $38.55 | +185.34% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $5.24 | +567.94% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.46 | +516.44% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $8.81 | -9.19% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $8.66 | +2,324.94% | 1 | Sep 2, 2020 |
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $56.90
Upside: +112.65%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $30.84
Upside: +45.91%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.98
Upside: +100.50%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $489.31
Upside: +15.26%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.22
Upside: +309.84%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.82
Upside: +1,963.36%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $31.97
Upside: +12.61%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $41.67
Upside: +29.59%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $10.61
Upside: -43.45%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.12
Upside: -2.34%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.54
Upside: +289.61%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $5.13
Upside: +36.45%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $234.13
Upside: +4.64%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.49
Upside: +247.13%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $11.61
Upside: -39.71%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $11.95
Upside: +134.31%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.92
Upside: +139.73%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $93.29
Upside: -4.60%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.91
Upside: +261.79%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $18.09
Upside: +126.64%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $39.38
Upside: -11.12%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $46.48
Upside: +177.54%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $3.95
Upside: +102.53%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $109.60
Upside: -11.50%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $38.55
Upside: +185.34%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $5.24
Upside: +567.94%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.46
Upside: +516.44%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $8.81
Upside: -9.19%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $8.66
Upside: +2,324.94%